韩国红人参 马克衍生的金素通过升级LPAR1来改善阿尔茨海默氏症的认知功能障碍
Yujeong Ha1,2, Rami Lee3, Seung Ho Jeon4
1Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
The American journal of Chinese medicine
|February 17, 2025
概括
韩国红人参 (KRGM-G) 基因素显示出治疗阿尔茨海默病的潜力,通过提高认知能力和减少大脑炎症和氧化应激.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 人参被公认为对大脑健康有好处,但活性化合物仍然难以捉摸.
- 人参中的一种化合物银素含有溶解酸 (LPA),是LPA受体 (LPARs) 的激动剂.
- 韩国红人参 (KRGM) 是一种富含KRGM衍生金素 (KRGM-G) 的副产品,含有功能性LPA.
研究的目的:
- 为了研究KRGM-G.对抗阿尔茨海默病 (AD) 的效果.
- 阐明KRGM-G治疗潜力的基础分子机制.
- 在AD模型中评估KRGM-G对认知功能,神经炎症和氧化应激的影响.
主要方法:
- 使用了转基因小鼠和SH-SY5Y神经母细胞瘤细胞的粉样β前体蛋白/前列林1 (APP/PS1).
- 用KRGM-G来评估认知能力的改善,粉样β积累和神经炎症标志物 (微质,星球细胞,促炎细胞因子).
- 评估了KRGM-G对细胞活力,活性氧物种 (ROS) 生产和关键信号通路 (MAPK,NF-κB,STAT3,Nrf2) 的影响.
主要成果:
- 在APP/PS1小鼠中,KRGM-G改善了认知缺陷,并降低了粉样β负担.
- 通过降低微质细胞和天体细胞活化以及亲炎性介质表达,KRGM-G抑制了神经炎症.
- KRGM-G增强了神经元活力,减少了ROS,并调节了信号通路,包括Nrf2激活和p38/NF-κB/STAT3抑制.
- 这些影响与LPA受体1 (LPAR1) 的上调有关.
结论:
- KRGM-G显示出对抗阿尔茨海默病的显著治疗潜力.
- 通过减轻神经炎症和氧化应激,KRGM-G具有神经保护作用.
- KRGM-G的抗AD机制涉及LPAR1激活,导致Nrf2通路刺激和炎症通路抑制.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的疾病.认知障碍 认知障碍是一种认知障碍.吉托尼尼是一种激素.韩国红人参 马克 韩国红人参lysophosphatidic 酸受体 1 lysophosphatidic 酸受体 1 是一种更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
03:26Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
Published on: December 8, 2023
1.0K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
